

Remarks

Reconsideration of this Application is respectfully requested.

In the Notice, the Examiner indicates that claim 69 recites SEQ ID NO:3877 wherein X can be cyclohexylalanine, while SEQ ID NO:3877 of the computer readable form of the sequence listing erroneously lists this residue as "cyclohexyalanine." Applicants file herewith an electronically submitted substitute sequence listing that corrects this obvious typographical error as requested by the Examiner. The substitute sequence listing also reflects the current title of the application.

The specification has been amended to insert the file name and other information for the substitute sequence listing and to incorporate it by reference as required by Part II of "Legal Framework for Electronic Filing System--Web (EFS-WEB)," 74 Fed. Reg. 55200 (October 27, 2009), and as per 37 C.F.R. § 1.52(e)(5). The specification has been amended to direct entry of the substitute sequence listing at the end of the application.

These changes are believed to introduce no new matter and their entry is respectfully requested.

Applicants note that the current application was filed on July 8, 1999. During the course of prosecution of the current application, Applicants have responded on multiple occasions to requests to correct the sequence listing and/or the specification with regard to formalities requirements. (*See, e.g.,* Notice to Comply with Requirements for Patent Applications Containing Nucleotide Sequence and/or Amino Acid Sequence Disclosures dated January 25, 2002, Notice to Comply with Requirements for Patent Applications Containing Nucleotide Sequence and/or Amino Acid Sequence Disclosures dated March

23, 2004, Notice of Noncompliant Amendment dated March 21, 2007, and Notice to Comply with Requirements for Patent Applications Containing Nucleotide Sequence and/or Amino Acid Sequence Disclosures dated March 16, 2011.)

The Manual of Patent Examining Procedure ("MPEP") provides guidance related to formalities requirements. For example, when outstanding formalities requirements are noted by the Office of Initial Patent Examination or by the Draftsperson, forms listing these requirements are placed in applications. *See* MPEP § 707.07(a). Such forms are to be mailed to Applicants as a part of the Examiner's first action:

[i]n every instance where these forms are to be used, they should be mailed with the examiner's *first* action, and any additional formal requirements which the examiner desires to make should be included in the *first* action.

MPEP § 707.07(a) (emphasis in original).


Additionally, the MPEP notes that "[p]iecemeal examination should be avoided as much as possible." MPEP § 707.07(g).

In view of at least the above-mentioned guidance in the MPEP and the reasons discussed above, Applicants respectfully request that the Examiner recommence substantive examination of the application. Applicants assert that any additional formalities requirements, if necessary, should be addressed once claims are found allowable.

If the Examiner believes, for any reason, that personal communication will expedite prosecution of this application, the Examiner is invited to telephone the undersigned at the number provided.

Respectfully submitted,

STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C.



Lori M. Brandes
Attorney for Applicants
Registration No. 57,772

Date: April 14, 2011

1100 New York Avenue, N.W.
Washington, D.C. 20005-3934
(202) 371-2600